Chikungunya Clinical Trial
Official title:
Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area
The clinical study primarily assesses the safety of MV-CHIK a new Chikungunya vaccine in a previously epidemic area in healthy volunteers. Secondarily, immune response and viremia will be assessed. MV-CHIK will be compared to the commercially available MMR vaccine. 80% of the subjects will receive MV-CHIK; 20% will receive MMR vaccine.
The clinical study to be conducted under this IND will assess the safety of MV-CHIK in a previously epidemic area (Puerto Rico). A total of 100 healthy volunteers, 50 of whom are seropositive to Chikungunya at baseline and 50 of whom are seronegative, will be randomized in a 4:1 ratio to receive either MV-CHIK or the commercially available MMR vaccine in a double blinded fashion. Memory aids, to be completed by the volunteer at home, and the investigator at scheduled follow-up visits, will solicit symptoms of injection site reactions, fever, headache, malaise, joint and muscle pain. Acute phase reactants (C-reactive protein and ferritin) will be checked routinely throughout the study and at the discretion of the investigator in order to help determine if symptoms, particularly those referred to the joints, have an immunological basis. This study will also evaluate the immune response in Chikungunya-exposed versus unexposed individuals by comparing neutralizing antibody titers at specific time points. Measles viremia will also be measured and compared between MV-CHIK and MMR recipients, and at three days after the second versus after the first dose. The relationship between measles viremia and the immune response to MV-CHIK will be explored. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT04440774 -
Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.
|
Phase 1 | |
| Completed |
NCT05153018 -
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
|
N/A | |
| Active, not recruiting |
NCT04343521 -
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
|
Phase 3 | |
| Completed |
NCT03992872 -
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
|
Phase 2 | |
| Completed |
NCT03382964 -
Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02831699 -
The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
|
||
| Recruiting |
NCT01099852 -
Cohort of Patients Infected by an Arbovirus
|
||
| Completed |
NCT06257810 -
Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa
|
Phase 4 | |
| Suspended |
NCT05218304 -
Baromètre Santé Adulte 2021-2022
|
N/A | |
| Recruiting |
NCT04615364 -
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
|
||
| Completed |
NCT04650399 -
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
|
Phase 3 | |
| Not yet recruiting |
NCT04672577 -
Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
|
||
| Completed |
NCT04434846 -
Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
|
||
| Recruiting |
NCT04838574 -
Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
|
||
| Recruiting |
NCT04619823 -
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
|
N/A | |
| Completed |
NCT02463968 -
Chikungunya Arthritis in the Americas
|
N/A | |
| Active, not recruiting |
NCT04566484 -
Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
|
Phase 2/Phase 3 | |
| Completed |
NCT04603131 -
Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine
|
Phase 1 |